Qiao Li

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 20

Top Topics

Epidermal Growth Factor Receptor

Ejection Fraction

Top Venues

International journal of cancer

Nature communications

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Mingxia Jiang, Jiaxuan Liu, Maiyue He, Mengqi Zhang, Shihan Zhou, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Pin Zhang, Binghe Xu, Qiao Li
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study. Therapeutic advances in medical oncology 16 (2024)
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li, Binghe Xu
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer. Cancer biology & medicine (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Qiao Li, Jiaxuan Liu, Qingyuan Zhang, Quchang Ouyang, Yang Zhang, Qiang Liu, Tao Sun, Feng Ye, Baochun Zhang, Summer Xia, Bangyong Zhang, Binghe Xu
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nature communications 15 (1) (2024)
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Zongbi Yi, Ying Fan, Peng Yuan, Bing-He Xu, Qiao Li
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. Therapeutic advances in medical oncology 15 (2023)
Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Zijing Wang, Fei Ma, Jiayu Wang, Peng Yuan, Yang Luo, Binghe Xu, Qiao Li
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer. Thoracic cancer (2023)
Mingxia Jiang, Jiaxuan Liu, Qiao Li, Binghe Xu
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status. International journal of cancer (2023)
Jiaxuan Liu, Maiyue He, Kaiping Ou, Xin Wang, Yipeng Wang, Liqiang Qi, Yue Chai, Mingxia Jiang, Zongbi Yi, Yang Luo, Peng Yuan, Pin Zhang, Binghe Xu, Qiao Li
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. International journal of cancer (2023)
Yue Chai, Yujie Chen, Jiaxuan Liu, Maiyue He, Mingxia Jiang, Binghe Xu, Qiao Li
Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population-based study in patients with breast cancer. Thoracic cancer (2023)
Meng Xiu, Pin Zhang, Xiang Wang, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Lin Dong, Yang Luo, Peng Yuan, Zongbi Yi, Bing-He Xu
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. International journal of cancer 151 (4) (2022)
Fei He, Jiaxuan Liu, Xin Shen, Zijing Wang, Qiao Li, Guohui Li
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. The Annals of pharmacotherapy 56 (8) (2021)
Yimeng Chen, Yin Guan, Jiayu Wang, Zongbi Yi, Yang Luo, Shanshan Chen, Pin Zhang, Qing Li, Ruigang Cai, Qiao Li, Hongnan Mo, Bo Lan, Xuelian Chen, Weihong Zhao, Bing-He Xu, Ying Fan
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. International journal of cancer 147 (12) (2020)
Zongbi Yi, Yanfang Guan, Zong-Bi Yi, Lianpeng Chang, Qiao Li, Shanshan Chen, Wenjie Zhu, Xiuwen Guan, Chunxiao Li, Haili Qian, Xuefeng Xia, Ling Yang, Jianjun Zhang, Hatim Husain, Zhongxing Liao, Andrew Futreal, Jian Huang, Xin Yi, Bing-He Xu
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International journal of cancer 146 (5) (2019)
Bo Lan, Fei Ma, Xiaoyu Zhai, Qiao Li, Shanshan Chen, Jiayu Wang, Ying Fan, Yang Luo, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International journal of cancer 143 (1) (2018)
Bo Lan, Fei Ma, Shanshan Chen, Wenna Wang, Qiao Li, Ying Fan, Yang Luo, Ruigang Cai, Jiayu Wang, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International journal of cancer 143 (10) (2018)